Evidence map›Paper›PMID 36777781›Full record

ArticleFrontiers in public health2022

Impact of comorbidity on patients with COVID-19 in India: A nationwide analysis.

Priya Singh, Yogendra Bhaskar, Pulkit Verma, Shweta Rana, Prabudh Goel, Sujeet Kumar, Krushna Chandra Gouda, Harpreet Singh

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Priya SinghDivision of Biomedical Informatics, Indian Council of Medical Research, New Delhi, India.
Yogendra BhaskarDivision of Biomedical Informatics, Indian Council of Medical Research, New Delhi, India.
Pulkit VermaDivision of Biomedical Informatics, Indian Council of Medical Research, New Delhi, India.
Shweta RanaDivision of Biomedical Informatics, Indian Council of Medical Research, New Delhi, India.
Prabudh GoelDepartment of Paediatric Surgery, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Sujeet KumarCentre for Proteomics and Drug Discovery, Amity University Maharashtra, Mumbai, India.
Krushna Chandra GoudaEarth and Engineering Sciences Division, CSIR Fourth Paradigm Institute, Bangalore, India.
Harpreet SinghDivision of Biomedical Informatics, Indian Council of Medical Research, New Delhi, India.
Indian Council of Medical Research · INAll India Institute of Medical Sciences · INFourth Paradigm Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The emergence of coronavirus disease (COVID-19) as a global pandemic has resulted in the loss of many lives and a significant decline in global economic losses. Thus, for a large country like India, there is a need to comprehend the dynamics of COVID-19 in a clustered way. Objective: To evaluate the clinical characteristics of patients with COVID-19 according to age, gender, and preexisting comorbidity. Patients with COVID-19 were categorized according to comorbidity, and the data over a 2-year period (1 January 2020 to 31 January 2022) were considered to analyze the impact of comorbidity on severe COVID-19 outcomes. Methods: For different age/gender groups, the distribution of COVID-19 positive, hospitalized, and mortality cases was estimated. The impact of comorbidity was assessed by computing incidence rate (IR), odds ratio (OR), and proportion analysis. Results: The results indicated that COVID-19 caused an exponential growth in mortality. In patients over the age of 50, the mortality rate was found to be very high, ~80%. Moreover, based on the estimation of OR, it can be inferred that age and various preexisting comorbidities were found to be predictors of severe COVID-19 outcomes. The strongest risk factors for COVID-19 mortality were preexisting comorbidities like diabetes (OR: 2.39; 95% confidence interval (CI): 2.31-2.47; Conclusion: This study concluded that elderly patients with preexisting comorbidities were at an increased risk of COVID-19 mortality. Patients in the elderly age group with underlying medical conditions are recommended for preventive medical care or medical resources and vaccination against COVID-19.

Indexed as

COVID-19Diabetes MellitusAgedComorbidityHumansRisk FactorsSARS-CoV-2comorbidityCOVID-19epidemiologyhypertensionodd ratio

Identifiers

PMID36777781
PMCPMC9911546
OpenAlexW4318191397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.